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Stage
CharacteristicsGender
Male 3
Female 10Age at Diagnosis
Mean 43 years
Median 43 years (range 34-48)Diagnosis
Multiple Myeloma 12
POEMS syndrome 1Feature n (%)
HGB < 100 g/L 6/13 (46.4)
Calcium > 2.75 mmol/L 1/13 (7.6)
Creatinine > 90 mmol/L 5/13 (38.5)
Albumin < 35 g/L 7/13 (53.8)
One or more lytic lesions 9/13 (69.2)
Clonal plasma cells > 10% 8/13 (61.5)
b2-microglobulin< 3.5 mg/L 4/13 (30.8)
3.5 mg/L - 5.5 mg/L 4/13 (30.8)
> 5.5 mg/L 5/13 (38.5)
Measurable M-protein 8/13 (61.5)Monoclonal protein
IgG 8/13 (61.5)
IgM 0/13
IgA 0/13Light Chains
kappa 5/13 (38.5)
lambda 6/13 (46.4)ISS
Stage 1 4/13 (30.8)
Stage 2 4/13 (30.8)
Stage 3 5/13 (38.5)256
SINGLE VERSUS TANDEM AUTOLOGOUS STEM CELL TRANSPLANTATION
(ASCT) FOR MULTIPLE MYELOMA PATIENTS AND ROLE OF SECOND SAL-
VAGE TRANSPLANT: A SINGLE CENTER PROSPECTIVE PHASE II STUDY
Moreb, J.S.1, Salmasinia, D.1, Leather, H.1, Davis, A.1, Hsu, J.W.1,
Wiggins, L.1, Cogle, C.R.1, Chang, M.N.2, Wingard, J.R.1 1University
of Florida, Gainesville, FL; 2University of Florida, Gainesville, FL
The role of tandem transplants as well as a later salvage second
transplant has been in the center of interest for manymyeloma inves-
tigators. Also, the need for tandem ASCT in patients (pts) achieving
very good partial remission (VGPR) or complete remission has not
been studied prospectively. We conducted a prospective phase II
clinical trial in which enrolledmyeloma pts are assessed after the first
ASCT and offered either 2nd tandem ASCT if they achieve# PR or
maintenance if they achieve $ VGPR. These latter pts received 2nd
salvage transplant after relapse. The conditioning regimens used
were different for the two ASCT: Busulfan 0.75 mg/kg PO q 6 hr
days -8 through -5, Cyclophosphamide (CP) 60 mg/kg IV days -3
and -2, and Etoposide 10 mg/kg IV days -4 to -2 for the first
ASCT, and 96 hr (days -6 to -3) continuous IV CP 6 gr/m2 and total
body irradiation (TBI) 600 cGy (days -2 and -1) for the second
ASCT. Etoposide was omitted if pts were $ 65 year old, and TBI
was substituted by melphalan 140 mg/m2 if prior radiation did not
allow TBI. Between the years 2001-2009, 76 pts were enrolled. Of
the 31 pts planned to have tandem ASCT, 20 received tandem
ASCT and 2 additional pts had tandem auto-allo transplants. The
primary reasons for not receiving the planned tandem ASCT were
lack of socioeconomic resources and physical co-morbidities. Main-
tenance treatment was offered to both groups of pts. There were no
treatment related mortalities in the ASCT pts. We compared the
progression-free (PFS) and overall (OS) survival following the first
ASCT between pts who received tandem ASCT (n 5 20) and pts
who received single ASCT (n 5 54). The median PFS for tandem
pts was 27 mo (range, 10-93) versus 28 mo for single ASCT (range,
4-99) (P 5 0.889); the OS was 38 mo (range, 11-120) versus 72 mo
(range, 5-136), respectively (P 5 0.293). At the present time, a totalof 7 (35%) and 30 (55%) pts are still alive in the tandem and single
ASCT groups, respectively. Among the tandem pts, 2 underwent sal-
vage ASCT and one non-myeloablative allogeneic transplant (allo-
SCT); while in the single ASCT group 6 had salvage ASCT and 6
had allo-SCT. All salvage transplants were done at a median of 37
mo (range, 8-91) from 1st ASCT. In conclusion, pts who achieve $
VGPR after 1st ASCT have similar PFS and may be better OS
than pts who had tandem ASCT. Thus, the use of such response cri-
teria may identify a group of lower risk pts that will do well without
the upfront tandem ASCT.
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AUTOLOGOUS AND ALLOGENIC STEM CELL TRANSPLANTATION RE-
SULTS IN MULTIPLE MYELOMA PATIENTS – SINGLE CENTER STUDY
Ghavamzadeh, A., Alimoghaddam, K., Jahani, M., Mousavi, S.A.,
Bahar, B., Iravani, M., Ghaffari, F., Jalili, M., Jalali, A. Tehran Uni-
versity of Medical Sciences, Tehran, Islamic Republic of Iran
Introduction:Multiplemyeloma is a hematologicmalignancywhich
best responses to high dose therapies (HDT). HDTwith autologous
stem cell transplantation (ASCT) is demonstrated for multiple mye-
loma treatment, although some studies suggest allogenic stem cell
transplantation as better choice for younger patients. Several studies
have shown the efficacy of intensive chemotherapy in increasing pro-
gression- free survival (PFS) and overall survival (OS) rates.
Patients and Methods: During study time, from 1992 till October
2011, we submitted 312 Multiple Myeloma patients. More than half
of patients weremale (male/female: 197/115).Median age of patients
was 50. They underwent autologous stem cell transplantation except
fifteen which received allogenic stem cell transplantation. Fifty six
from 297 (18.8%) ASCT followed as outpatient. ASCT patients re-
ceived high dose melphalan (100 mg/m2) for 2 days and allogenic
stem cell transplanted (ALSCT) patients were conditioned with flu-
darabin (30 mg/m2) for 5 days and melphalan (100 mg/m2) for 2
days. Nearly total of patients received stem cells via peripheral blood
source (only four received bone marrow). All patients received gran-
ulocyte colony- stimulating growth factor.
Results: During median follow up of 22 months (1-165), 280/312
(89%) are alive. Eighty eight percent of patients were in complete re-
mission before transplantation. Neutrophils (ANC$0.5 10 9/L)
and platelets ($ 20 10 9/L) recovered in median times of 12 and
18 days, respectively. Fourty percent of allogenic transplanted pa-
tients affected with acute Graft Versus Host Disease with preferable
grade I and II. In ALSCT group with median follow up of nine
months relapse was not seen. The cumulative incidence of relapse
in two years was 21.2% (CI: 15.9- 27%). Two years disease free sur-
vival (DFS) and overall survival (OS) was 75.7% (SE: 2.9%), 92.3%
(SE: 7.4%) with p5 0.422 and 89.5% (SE: 2.1%), 92.3% (SE: 7.4%)
with p 5 0.96 in ASCT and ALSCT, respectively.
Conclusion: In this retrospective study, we found that although the
two years OS were equal in two groups, but the greater DFS in
ALSCT group shows less relapse rate in this group. The median du-
ration of hematologic recovery after ASCT and ALSCT did not dif-
fer significantly. The most common cause of death in ASCT was
relapse. Similarly to other studies, relapse rate after allogenic trans-
plantation is less than autologous. There is no significant p value in
OS and DFS because of low cases of ALSCT.
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CAN PATIENTS AGE 65 AND OLDER EXPERIENCE THE SAME OUTCOMES
COMPARED TO PATIENTS YOUNGER THAN AGE 65 FOR AUTOLOGOUS
STEM CELL TRANSPLANTATION IN MULTIPLE MYELOMA? A SINGLE IN-
STITUTION REVIEW
Gandhi, N., Abou Hussein, A.K., Fidler, C.J., Karur, V., Sharma, M.,
Klumpp, T.R., Kropf, P.R., Martin, M.E., Emmons, R.V.B.,
Mangan, K.F. Temple University Health System, Philadelphia, PA
High dose melphalan followed by an autologous stem cell trans-
plant has been shown to improve progression-free and overall sur-
vival in the treatment of multiple myeloma. It is unknown whether
the age of a patient receiving an autologous stem cell transplant for
multiple myeloma has an impact on treatment-related mortality
and overall outcome.
A retrospective review was performed of multiple myeloma pa-
tients transplanted at Temple Bone Marrow Transplant program
